MOLECULAR INDICATORS OF BLADDER CANCER PROGNOSIS AND PREDICTION OF TREATMENT RESPONSE

摘要

Disclosed are biomarkers, methods and assay systems for the identification of bladder cancer patients who are predicted to benefit, or not benefit from the therapeutic administration of neoadjuvant therapy. Particularly, the invention provides a diagnostic paradigm based on each of these tests and combinations of these tests to select bladder cancer patients who will or will not benefit from neoadjuvant chemotherapy, as well as a diagnostic paradigm to identify bladder cancer patients likely to suffer recurrence of cancer following cystectomy.